Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical medicine"
DOI: 10.7861/clinmed.22-4-s48
Abstract: Long-term safety: 94% of 48 TSC patients with refractory epilepsy maintained improved seizure control over 4 years; safe and tolerable. Adverse effects decreased over time. White matter modification: Everolimus pharmacologically modifies the genetic defect of… read more here.
Keywords: review mtor; inhibitor treatment; treatment biomarkers; systematic review ... See more keywords